Compare BridgeBio Pharma Inc (BBIO) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Sirius XM Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while Sirius XM Holdings Inc trades at $30.5 (market cap $10.23B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.55% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SIRI | |
|---|---|---|
Market Cap | $16.46B | $10.23B |
Sector | Health | Media |
52-Week High | $90.17 | $30.75 |
52-Week Low | $44.81 | $19.92 |
Enterprise Value | $18.02B | $19.90B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Sirius XM Holdings (SIRI) trades at $30.67, up 0.82% with strong technical momentum and bullish moving average signals. The company shows improved fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after a challenging 2024. Recent developments include a strategic advertising partnership with YouTube and potential merger discussions with iHeartMedia, driving positive investor sentiment.
The outlook remains positive with analysts maintaining a $31.17 consensus target and 58% buy ratings. Key opportunities include revenue diversification through new partnerships and strong cash flow generation supporting dividends and buybacks. Risks include intense media competition and high debt levels despite recent improvement from 94% to 36% debt-to-asset ratio since 2022.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
